Prospective phase II trial for recurrent high-grade malignant gliomas with capacitive coupled low radiofrequency (LRF) deep hyperthermia

Abstract

Treatment of malignant gliomas is in spite of many new approaches still disappointing. Median survival time (MST) of pts. with glioblastoma multiforme (GM) after diagnosis is 6 to 12 months. Surgery is treatment of first choice, but in most cases healing is not possible. The aims of surgery are tumor debulking or decompression of the brain. Radiation will double MST after surgery but high grade gliomas are not very radiosensitivesurvival. Concomitant radiation with temozollamide could increase median survival time of pts with GM from 12.1 to 14.6 months.